| P2093 | author name string | Fanos V | |
| | Testa M | |
| | Cuzzolin L | |
| | Atzei A | |
| P2860 | cites work | Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum | Q24247728 |
| | Chloramphenicol toxicity in neonates: its incidence and prevention | Q24675357 |
| | Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin | Q29041179 |
| | Imipenem/Cilastatin | Q29400850 |
| | Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid | Q33339926 |
| | Antibacterial-induced nephrotoxicity in the newborn | Q33604536 |
| | Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study | Q33803255 |
| | Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit | Q33856434 |
| | Antibiotic prophylaxis in children with relapsing urinary tract infections: review | Q33902960 |
| | Activities of linezolid against rapidly growing mycobacteria | Q33981613 |
| | Nosocomial spread of ceftazidime-resistant Klebsiella pneumoniae strains producing a novel class a beta-lactamase, GES-3, in a neonatal intensive care unit in Japan | Q34139810 |
| | Cephalosporin allergy | Q34369184 |
| | Role of erythromycin for treatment of incipient chronic lung disease in preterm infants colonised with Ureaplasma urealyticum | Q34439254 |
| | Once daily dosing of gentamicin in infants and children | Q34461152 |
| | Newborns and gentamicin--how much and how often? | Q34467489 |
| | Overview of the lipid formulations of amphotericin B. | Q34501018 |
| | Amphotericin B nephrotoxicity | Q34501024 |
| | In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms | Q35014416 |
| | The effect of postnatal age on gentamicin pharmacokinetics in neonates | Q35200868 |
| | Influence of erythromycin on establishment of feeding in preterm infants: observations from a randomised controlled trial | Q35287526 |
| | Outbreak of extended spectrum beta lactamase producing Klebsiella pneumoniae in a neonatal unit | Q35287858 |
| | Linezolid pharmacokinetics in pediatric patients: an overview | Q35547652 |
| | In vitro displacement of bilirubin by antibiotics and 2-hydroxybenzoylglycine in newborns | Q35564504 |
| | Strategies for prevention of neonatal invasive candidiasis | Q35588509 |
| | Once-daily gentamicin dosing for the preterm and term newborn: proposal for a simple regimen that achieves target levels | Q35597011 |
| | Antibiotic use in the neonatal unit | Q35603575 |
| | Antifungals in systemic neonatal candidiasis | Q35752870 |
| | Vancomycin: pharmacokinetics and administration regimens in neonates | Q35771508 |
| | Extended-interval aminoglycoside administration for children: a meta-analysis | Q35825369 |
| | Strategic use of antibiotics in the neonatal intensive care unit | Q35915310 |
| | Antibiotics or surgery for vesicoureteric reflux in children | Q35941694 |
| | Infection in the preterm infant | Q35963448 |
| | New dosing strategies for antibacterial agents in the neonate | Q36035169 |
| | Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. | Q36493837 |
| | Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age. | Q37909232 |
| | Safety of parenteral third-generation cephalosporins | Q37915964 |
| | Clinical pharmacokinetics of antibacterial drugs in neonates | Q37956835 |
| | Vancomycin ototoxicity and nephrotoxicity. A review | Q39542494 |
| | Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis | Q39579851 |
| | Pharmacokinetic interactions of the macrolide antibiotics | Q39814639 |
| | Modern beta-lactam antibiotics | Q39843101 |
| | Pharmacokinetics of imipenem-cilastatin in neonates | Q39849539 |
| | Single-dose pharmacokinetics of imipenem-cilastatin in neonates | Q39849620 |
| | Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia | Q39882511 |
| | Pharmacokinetics and renal tolerance of aztreonam in premature infants | Q40087264 |
| | The cephalosporin compounds in severe neonatal infection | Q40140366 |
| | Pharmacokinetics of anti-infective agents in paediatric patients | Q40686147 |
| | Adverse drug reactions in neonates | Q40743354 |
| | A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity | Q40865599 |
| | Intravenous trimethoprim-sulfamethoxazole in the treatment of serious infections in children | Q41108916 |
| | Meropenem: a new, extremely broad spectrum beta-lactam antibiotic for serious infections in pediatrics | Q41390923 |
| | Use of meropenem in the treatment of serious infections in children: review of the current literature | Q41451178 |
| | A review of teicoplanin in the treatment of serious neonatal infections | Q41518598 |
| | Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention | Q41686944 |
| | Beta-lactam antibiotics: their role in the management of infections in children | Q41728584 |
| | Outbreak of cephalosporin resistant Enterobacter cloacae infection in a neonatal intensive care unit | Q42138748 |
| | Activity of linezolid against anaerobic bacteria | Q42167831 |
| | Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia | Q42279188 |
| | Tobramycin population pharmacokinetics in neonates. | Q42666715 |
| | Gentamicin usage in newborns: an audit | Q43028658 |
| | Pharmacokinetics and dose requirements of vancomycin in neonates | Q43097632 |
| | Nosocomial bacterial infections in very low birth weight infants | Q43477048 |
| | Detection of antimicrobial resistance and extended-spectrum beta-lactamase production in Klebsiella pneumoniae strains from infected neonates | Q43487272 |
| | Erythromycin as a prokinetic agent in preterm infants | Q43830670 |
| | Comparative toxicities of third-generation cephalosporins | Q44035742 |
| | Predictability of peak serum gentamicin concentration with dosage based on body surface area | Q44048762 |
| | Thrombocytopenia secondary to linezolid administration: what is the risk? | Q44062192 |
| | Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss | Q44273563 |
| | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 |
| | Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit | Q44563016 |
| | Use of teicoplanin in preterm neonates with staphylococcal late-onset neonatal sepsis | Q44665783 |
| | Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life | Q44700606 |
| | Extended interval dosing of gentamicin in preterm infants | Q44797377 |
| | Selective use of vancomycin to prevent coagulase-negative staphylococcal nosocomial bacteremia in high risk very low birth weight infants | Q44809658 |
| | Use of ciprofloxacin in neonatal sepsis: lack of adverse effects up to one year | Q44835358 |
| | Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants | Q44918246 |
| | Safety evaluation of piperacillin/tazobactam in very low birth weight infants | Q44951211 |
| | Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. | Q44984663 |
| | Pharmacology of trimethoprim-sulfamethoxazole in newborn infants | Q45048038 |
| | Surveillance for transmission and antibiotic adverse events among neonates and adults exposed to a healthcare worker with pertussis | Q45164156 |
| | Outbreak of SHV-5 beta-lactamase-producing Klebsiella pneumoniae in a neonatal-pediatric intensive care unit in Spain | Q45223909 |
| | Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network | Q46360821 |
| | Intravenous voriconazole therapy in a preterm infant | Q46520649 |
| | Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network | Q47180140 |
| | Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants | Q47230879 |
| | Growth and development in preterm infants receiving fluoroquinolones. | Q51006897 |
| | Erythromycin fails to improve feeding outcome in feeding-intolerant preterm infants. | Q51534522 |
| | Fatal hemolysis caused by ceftriaxone. | Q53804496 |
| | Staphylococcus epidermidisIsolation and Antibiotic Resistance in a Neonatal Intensive Care Unit | Q54181982 |
| | A comparison of ceftazidime and aminoglycoside based regimens as empirical treatment in 1316 cases of suspected sepsis in the newborn. European Society for Paediatric Infectious Diseases--Neonatal Sepsis Study Group. | Q54256397 |
| | Use of Percutaneous Silastic Central Venous Catheters in Neonates and the Management of Infectious Complications | Q54266537 |
| | Chloramphenicol in paediatrics: current prescribing practice and the need to monitor. | Q54609196 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| | intensive care unit | Q5094647 |
| P304 | page(s) | 5-20 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Journal of Chemotherapy | Q15754073 |
| P1476 | title | Antibiotics and antifungals in neonatal intensive care units: a review | |
| P478 | volume | 19 | |